On June 3, RemeGen fell 5.02% in regular trading, trading at HKD 72.7/share, with trading volume of HKD 159 million, extending its recent downtrend.

On the news front, US legislators recently proposed including biotechnology in the scope of the COINS Act, aiming to restrict American capital from flowing into Chinese innovative drug companies. Simultaneously, market rumors suggest that domestic regulators plan to impose pre-approval requirements on overseas business development transactions for innovative drug firms. The dual escalation of US-China regulatory barriers has directly undermined the core valuation logic of the sector.

Additionally, Orient Securities previously reduced its holdings in RemeGen by 160,000 shares, while ETF funds have continued to see net outflows for multiple consecutive days. Sector-wide weakness is evident, with AKESO down 3.19%, 3SBIO down 3.68%, Innovent Bio down 2.92%, BeiGene down 2.07%, and SKB Bio down 3.42%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)